Janneke E. Jaspers

3.2k total citations · 1 hit paper
17 papers, 2.0k citations indexed

About

Janneke E. Jaspers is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Janneke E. Jaspers has authored 17 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Janneke E. Jaspers's work include DNA Repair Mechanisms (7 papers), PARP inhibition in cancer therapy (7 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Janneke E. Jaspers is often cited by papers focused on DNA Repair Mechanisms (7 papers), PARP inhibition in cancer therapy (7 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Janneke E. Jaspers collaborates with scholars based in Netherlands, United States and United Kingdom. Janneke E. Jaspers's co-authors include Sven Rottenberg, Jos Jonkers, Ariena Kersbergen, Piet Borst, Serge A.L. Zander, Aaron Cranston, Mark J. O’Connor, Niall M.B. Martin, Alan Lau and Renier J. Brentjens and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and PLoS ONE.

In The Last Decade

Janneke E. Jaspers

17 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

2008 762 citations Sven Rottenberg, Janneke E. Jaspers et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Janneke E. Jaspers Netherlands	15	1.5k	1.4k	388	284	226	17	2.0k
Eline van der Burg Netherlands	13	1.3k 0.8×	1.2k 0.8×	342 0.9×	262 0.9×	146 0.6×	19	1.7k
Elizabeth Ruth Plummer United Kingdom	19	961 0.6×	836 0.6×	152 0.4×	181 0.6×	116 0.5×	69	1.3k
Yvette Drew United Kingdom	22	1.8k 1.2×	1.4k 1.0×	333 0.9×	233 0.8×	170 0.8×	68	2.3k
Patrick G. Pilié United States	13	1.1k 0.7×	1.1k 0.8×	135 0.3×	342 1.2×	407 1.8×	43	1.8k
Céline Jacquemont United States	13	994 0.7×	1.2k 0.8×	347 0.9×	293 1.0×	115 0.5×	22	1.6k
Maria Orr United Kingdom	12	1.3k 0.9×	794 0.6×	473 1.2×	363 1.3×	273 1.2×	16	1.8k
Amèlie Renaud United States	6	2.0k 1.3×	1.7k 1.2×	265 0.7×	132 0.5×	245 1.1×	7	2.4k
Eva Schut Netherlands	13	707 0.5×	879 0.6×	269 0.7×	228 0.8×	96 0.4×	15	1.3k
Bose Kochupurakkal United States	16	810 0.5×	1.0k 0.7×	97 0.3×	183 0.6×	169 0.7×	44	1.4k
Leslie A. Parsels United States	24	1.4k 0.9×	1.5k 1.1×	75 0.2×	349 1.2×	289 1.3×	39	2.1k

Countries citing papers authored by Janneke E. Jaspers

Since Specialization

Citations

This map shows the geographic impact of Janneke E. Jaspers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janneke E. Jaspers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janneke E. Jaspers more than expected).

Fields of papers citing papers by Janneke E. Jaspers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janneke E. Jaspers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janneke E. Jaspers. The network helps show where Janneke E. Jaspers may publish in the future.

Co-authorship network of co-authors of Janneke E. Jaspers

This figure shows the co-authorship network connecting the top 25 collaborators of Janneke E. Jaspers. A scholar is included among the top collaborators of Janneke E. Jaspers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janneke E. Jaspers. Janneke E. Jaspers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Jaspers, Janneke E., et al.. (2023). IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. Journal of Clinical Investigation. 133(9). 96 indexed citations

Jaspers, Janneke E. & Renier J. Brentjens. (2017). Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacology & Therapeutics. 178. 83–91. 86 indexed citations

O’Connor, Lenka Oplustil, Stuart L. Rulten, Aaron Cranston, et al.. (2016). The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer Research. 76(20). 6084–6094. 60 indexed citations

Warmoes, Marc O., Siu W. Lam, Petra van der Groep, et al.. (2016). Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. Oncotarget. 7(39). 63537–63548. 14 indexed citations

Henneman, Linda, Martine H. van Miltenburg, Ewa M. Michalak, et al.. (2015). Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proceedings of the National Academy of Sciences. 112(27). 8409–8414. 95 indexed citations

Jaspers, Janneke E., Wendy Sol, Ariena Kersbergen, et al.. (2014). BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance. Cancer Research. 75(4). 732–741. 53 indexed citations

Spliethoff, Jarich W., Daniel J. Evers, Janneke E. Jaspers, et al.. (2014). Monitoring of Tumor Response to Cisplatin Using Optical Spectroscopy. Translational Oncology. 7(2). 230–239. 13 indexed citations

Warmoes, Marc O., Janneke E. Jaspers, Guotai Xu, et al.. (2013). Proteomics of Genetically Engineered Mouse Mammary Tumors Identifies Fatty Acid Metabolism Members as Potential Predictive Markers for Cisplatin Resistance. Molecular & Cellular Proteomics. 12(5). 1319–1334. 25 indexed citations

Westerweel, Peter E., Martin Teraa, Shahin Rafii, et al.. (2013). Impaired Endothelial Progenitor Cell Mobilization and Dysfunctional Bone Marrow Stroma in Diabetes Mellitus. PLoS ONE. 8(3). e60357–e60357. 54 indexed citations

10.

Jaspers, Janneke E., Ariena Kersbergen, Ute Boon, et al.. (2012). Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors. Cancer Discovery. 3(1). 68–81. 388 indexed citations

11.

Warmoes, Marc O., Janneke E. Jaspers, Thang V. Pham, et al.. (2012). Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer. Molecular & Cellular Proteomics. 11(7). M111.013334–1. 24 indexed citations

12.

Issaeva, Natalia, Huw D. Thomas, Janneke E. Jaspers, et al.. (2010). 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research. 70(15). 6268–6276. 80 indexed citations

13.

Zander, Serge A.L., Ariena Kersbergen, Eline van der Burg, et al.. (2010). Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan. Cancer Research. 70(4). 1700–1710. 66 indexed citations

14.

Hammers, Hans J., Henk M.W. Verheul, Brenda Salumbides, et al.. (2010). Abstract 388: Epithelial to mesenchymal transition is associated with acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Cancer Research. 70(8_Supplement). 388–388. 1 indexed citations

15.

Hammers, Hans J., Henk M.W. Verheul, Brenda Salumbides, et al.. (2010). Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study. Molecular Cancer Therapeutics. 9(6). 1525–1535. 141 indexed citations

16.

Jaspers, Janneke E., Sven Rottenberg, & Jos Jonkers. (2009). Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1796(2). 266–280. 31 indexed citations

17.

Rottenberg, Sven, Janneke E. Jaspers, Ariena Kersbergen, et al.. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences. 105(44). 17079–17084. 762 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact